Divi's Laboratories (NSE:DIVISLAB): What Is the Special Window for Physical Share Transfer and Dematerialisation?
NiveshIQ
NSE: DIVISLAB · Pharma
Divi's Laboratories Ltd.
₹9,322.00▼ ₹116.50 (-1.23%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on DIVISLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Divi's Laboratories Ltd.
Divi's Laboratories Limited is a leading manufacturer of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals, with a strong presence in India, North America, Asia, Europe, and internationally. The company's core business is driven by its API and intermediate segments, which account for a significant portion of its revenue. Recent developments, such as the company's Q1 FY27 results, have shown a 65.5% increase in profit to ₹902 crore, driven by strong revenue growth of 27.8% year-over-year, with net sales reaching ₹3,080 crore. Divi's Laboratories has a competitive position in the market, with a diverse product portfolio and a strong export network. The company's growth outlook is positive, with analysts expecting continued revenue growth driven by increasing
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹7,845 Cr +1.00% | ₹9,360 Cr +19.30% | ₹10,560 Cr +12.80% |
| EBITDA Margin | 28.08% | 31.70% | 37.39% |
| Net Profit | ₹1,600 Cr -12.20% | ₹2,191 Cr +36.90% | ₹2,642 Cr +20.60% |
| EPS | ₹60.28 | ₹82.54 | ₹96.75 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Dr. Reddy's Laboratories Share Price: valuation and peers
Brooks Laboratories Share Price rises 8.56% to Rs 69.01
🔒
+ 3 more stories about Divi's Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹3, 080 Cr, PAT ₹902 Cr, EPS ₹33.95, EBITDA margin 42.8%. Growth context: revenue QoQ +8.8%, PAT QoQ +20.1%. Street verdict: strong beat, revenue surprise +11.6%, PAT surprise +37.7%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement as the primary near-term g...
FY26 (last completed FY): revenue ₹10, 560 Cr, PAT ₹2, 642 Cr, EBITDA margin 37.4%, EPS ₹96.75. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for DIVISLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track DIVISLAB alongside your other holdings
Unlock full DIVISLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Divi's Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Divi's Laboratories Ltd. (DIVISLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Divi's Laboratories Ltd.?
Divi's Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹20,799,463.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.